Trials
1 active
2 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “normal cognitive function, mild cognitive impairment (MCI) caused by Alzheimer's disease (AD) using \[18F\]Fluorbetazine injection.”In the company’s words, NCT07764679 on ClinicalTrials.gov
- Tested for
- Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
- Main trialPhase 3
- “A multicenter phase III clinical study evaluating the diagnostic performance and safety of PET for the deposition of Aβ plaques in the brain of participants with normal cognitive function, MCI and AD using \[18F\]Fluorbetazine injection.”In the company’s words, NCT07764679 on ClinicalTrials.gov
- Other names
- Fluorbetazine
Other drugs for Mild Cognitive Impairment (MCI)
- LecanemabEisai · Biogen · Phase 3
- Verenafusp alfaAO GENERIUM · Phase 2/3
- Buntanetap/posiphenAnnovis Bio Inc. · Phase 3
- TrontinemabRoche · Phase 3
- DonanemabEli Lilly · Phase 3
- Xanomeline/Trospium ChlorideBristol Myers Squibb · Phase 3
Coming up1
- 31 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Dec 2027 | A Clinical Study Evaluating the Diagnostic Performance and Safety of PET for the Deposition of Aβ Plaques in the Brain of Participants With Normal Cognitive Function, MCI and AD Using [18F]Fluorbetazine Injection | |
| Phase 1Completed | 30 Jun 2025 | A Phase I Clinical Study on the Safety and Pharmacokinetics of [18F]Florbetazine Injection |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026